State Street Corp Cellectis S.A. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$2.29 - $4.08 $19,792 - $35,263	8,643 Added 3.41%	262,368 $601,000
Q2 2022 Aug 15, 2022	BUY	$2.39 - $4.93 $320,651 - $661,428	134,164 Added 112.21%	253,725 $718,000
Q1 2022 May 16, 2022	BUY	$3.45 - $8.77 $14,824 - $37,684	4,297 Added 3.73%	119,561 $543,000
Q4 2021 Feb 14, 2022	BUY	$8.01 - $12.84 $765,924 - $1.23 Million	95,621 Added 486.79%	115,264 $936,000
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $4,871 - $6,564	408 Added 2.12%	19,643 $248,000
Q2 2021 Aug 16, 2021	SELL	$14.36 - $20.93 $266,636 - $388,628	-18,568 Reduced 49.12%	19,235 $298,000
Q1 2021 May 17, 2021	SELL	$18.19 - $33.25 $33,342 - $60,947	-1,833 Reduced 4.62%	37,803 $764,000
Q4 2020 Feb 16, 2021	SELL	$15.87 - $31.64 $336,444 - $670,768	-21,200 Reduced 34.85%	39,636 $1.07 Million
Q3 2020 Nov 10, 2020	SELL	$15.7 - $20.84 $9,388 - $12,462	-598 Reduced 0.97%	60,836 $1.13 Million
Q2 2020 Aug 14, 2020	BUY	$8.21 - $21.02 $504,373 - $1.29 Million	61,434 New	61,434 $1.09 Million

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $88.3M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.